Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Top Research Reports For Merck, Eli Lilly & Charter Communications

Published 11/27/2019, 03:53 AM
Updated 07/09/2023, 06:31 AM

Wednesday, November 27, 2019

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Eli Lilly (LLY) and Charter Communications (NASDAQ:CHTR) (CHTR). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Merck’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry year to date (+11.7% vs. +6.2%). The Zacks analyst believes that Merck’s products like Keytruda, Lynparza and Bridion are driving sales.

Keytruda sales are gaining from continued uptake in lung cancer and increased usage in other cancer indications. Keytruda has strong growth prospects based on increased utilization, recent approvals for new indications and potential additional approvals worldwide. Animal health and vaccine products are also performing strongly and remain core growth drivers for Merck.

However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competitive pressure on the diabetes franchise and on products like Isentress and Zepatier remains a concern.

(You can read the full research report on Merck here >>>)

Shares of Eli Lilly have gained 5.8% in the past three months against the Zacks Large Cap Pharmaceuticals industry’s rise of 8.1%. The Zacks analyst believes that Lilly’s revenue growth is being driven by higher demand for its newer drugs including Trulicity, Jardiance, Taltz, Verzenio and new migraine drug, Emgality.

Lilly has made significant pipeline progress in the past year with several positive late-stage data readouts, multiple approvals and regulatory submissions. Lilly also added promising new pipeline assets through business development deals.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

However, rising competitive pressure on Lilly’s drugs, generic competition for several drugs including Cialis, rising pricing pressure in the United States, price cuts in some international markets, currency headwinds and the impact of the failed Lartruvo study are putting pressure on the top line.

(You can read the full research report on Eli Lilly here >>>)

Charter Communications' shares have gained 23.5% over the past six months against the Zacks Cable TV industry's rise of 7.3%. The Zacks analyst believes that the company is benefiting from growth in Internet, mobile, commercial and video revenues.

Increase in Internet speed at no extra cost is also aiding subscriber growth. Additionally, Charter’s spectrum mobile products are gaining traction and subscriber base is increasing rapidly. Launch of spectrum mobile services to small and medium business customers is a key catalyst. Improving free cash flow is a growth driver.

However, commercial revenues continued to suffer due to migration of customers to Spectrum pricing, and packaging from Legacy TWC and Legacy Bright House. Further, Charter persistently loses video subscribers, primarily due to cord-cutting and intense competition from streaming service providers like Netflix (NASDAQ:NFLX) and Amazon (NASDAQ:AMZN).

(You can read the full research report on Charter Communications here >>>)

Other noteworthy reports we are featuring today include Intuit (INTU), Alibaba (NYSE:BABA) Group (BABA) and Charles Schwab (SCHW).

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

See the pot trades we're targeting>>

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Featured Reports

Intuit (INTU) Rides on Solid Product Portfolio & Cloud Shift

Per the Zacks analyst, Intuit is gaining from solid adoption of TurboTax Live offering, and its lending product - QuickBooks Capital.

Alibaba (BABA) Drives On Cloud Growth; Investments Hurt

Per the Zacks analyst, Alibaba benefits from e-commerce business, cloud services & international growth. However, higher costs associated with new initiatives is a concern.

Acquisitions, Trading Focus Aid Schwab (SCHW) Amid Low Rates

Per the Zacks analyst, Schwab's planned buyouts of TD Ameritrade and USAA's Investment Management Company will help diversify revenues.

Systematic Investments, Strong Cash Flow Aid Exelon (NASDAQ:EXC)

Per the Zacks analyst Exelon's $22.6 billion long term investment plan will assist to lower debts and fund growth.

E-commerce Growth Aids FedEx (NYSE:FDX) Amid Express Unit Woes

Per the Zacks analyst, FedEx is benefiting from rising package volumes, courtesy of rapid e-commerce growth.

Pasadena Terminal to Aid Valero (VLO), High Corn Prices Ail

Valero's Pasadena terminal, expected to come online in 2020, will boost profits from exports. However, the Zacks analyst is concerned over rising corn prices that are affecting the ethanol business.

Brown-Forman's (BF.B) Solid Underlying Sales to Boost Growth

Per the Zacks analyst, Brown-Forman is experiencing solid underlying sales growth due to strength in its major brands. This along with constant investments in its brand portfolio is aiding results.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
New Upgrades

Organic Growth & Strategic Acquisitions Aid Jones Lang (JLL)

Per the Zacks Analyst, solid growth in Real Estate Services segment fuels Jones Lang LaSalle's organic growth. Strategic buyouts and technology investments provides it a competitive edge.

Cirrus Logic (CRUS) Rides on Strengthening Product Portfolio

Per the Zacks analyst, Cirrus Logic's expanding product portfolio comprising audio, voice and other adjacent market items, such as haptics, is a key driver.

Fleet Upgrade & Passenger Revenues Boost Allegiant (ALGT)

The Zacks analyst is impressed with passenger revenue growth at Allegiant owing to strong demand for air travel. Efforts to modernize its fleet are also encouraging.

New Downgrades

Fluctuating Commodity Price, High Debts Ail Occidental (NYSE:OXY)

Per the Zacks analyst increased debt level due to loan taken by Occidental to fund acquisition of Anadarko and fluctuating commodity prices is hampering its profitability.

Weak Pressure Pumping Market to Hurt ProPetro (PUMP)

The Zacks analyst is concerned over the weak market sentiment and lower pricing with respect to pressure pumping services in the Permian Basin, which is expected to weigh on ProPetro's revenues.

GoPro (GPRO) Hurt by Production Delay Amid Stiff Competition

Per the Zacks analyst, GoPro is likely to be hit by a delay in production of its Hero8 Black cameras. It trimmed its 2019 revenue outlook due to intense competition in camera and camcorder market.


undefined undefined

The Charles Schwab Corporation (NYSE:SCHW): Free Stock Analysis Report

Merck & Co., Inc. (MRK): Free Stock Analysis Report

Eli Lilly and Company (NYSE:LLY): Free Stock Analysis Report

Intuit Inc. (NASDAQ:INTU): Free Stock Analysis Report

Charter Communications, Inc. (CHTR): Free Stock Analysis Report

Alibaba Group Holding Limited (BABA): Free Stock Analysis Report

Original post

Zacks Investment Research

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.